ORCID is part of the wider digital infrastructure needed for researchers to share information on a global scale. ORCID enables transparent and trustworthy connections between researchers, their contributions, and affiliations by providing an identifier for individuals to use with their name as they engage in research, scholarship and innovation activities. The Open Pharma community is … Continue reading Guest post: ORCID adoption in the pharma community
Finding a good book to read on holiday may sometimes be a challenge. Luckily, the Open Pharma team is here to help with its shortlist of the best reads for summer 2019!
The Association of the British Pharmaceutical Industry (ABPI) has said that it wants to take transparency to the next level, and has committed to making clinical research more accessible and understandable across the pharmaceutical industry.
At a workshop on managing conflicts of interest in medicine, Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, argued for openness.
On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the 8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.
The Good Practice for Conference Abstracts and Presentations (GPCAP) recommendations have been developed to address the challenges faced by industry professionals and authors when preparing abstracts and presentations for academic conferences.
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
Last week’s ISMPP-U webinar ‘Open Access and Medical Publishing’, developed by the Medical Publishing Insights & Practices (MPIP) initiative and Open Pharma and moderated by LaVerne Mooney (Pfizer) and Chris Winchester (Oxford PharmaGenesis), aimed to define the key elements of open access policies, to provide insight into the changing publishing environment and to understand the perspectives of non-commercial and commercial stakeholders on open access publishing.
In recent years, open access has provided new audiences, including patients, the general public and doctors in low and middle income countries (LMICs), with direct, free access to the results of scientific research.
In order to protect the quality of clinical research it is vital for all trials to be represented in scientific literature for the benefit of scientific progress and research efficiency, and, ultimately, to better inform care for our patients in a timely manner.